The board began rescinding unnecessary interim policies, heard rulemaking updates, and a licensee called for more time to transition from seed-to-sale traceability to weekly reporting.
A single patient offered testimony recommending sales tax breaks be reserved for registered patient purchases of DOH compliant products to incentivize “medical grade” production.
A public hearing on the implementation of imported CBD rules drew suggested revisions on cannabis product testing standards from the public and a WSDA pesticide official.
The social equity task force was scheduled to review significant legislative proposals developed by work group members, and WSDA opened its pesticide penalty regime for revision.
The board heard about two agency request bills: a joint venture with WSDA to regulate testing lab standards and one “to allow for synthetic, but to prohibit artificial” cannabinoids in products.
Staff provided more specifics on processes and standards for compliance reporting under the Cannabis Central Reporting System (CCRS) and responded to 50 pre-submitted questions.
Commissioners adopted a six-month moratorium on permitting of new cannabis producers or expansion of grows, and required existing businesses to corroborate site plan documentation.
Following a longer development process than expected, a CR-102 on CBD imports for use as cannabis product additives was presented to board members and gained their approval.
Summer is “officially” over as judged by policymaking on traceability, 2022 legislation, synthesized cannabinoids, and medical cannabis taxation in the week ahead.
Commissioners learned about tax exemptions for medical patients and cooperatives, and the potentially dramatic impact of a statutory change redefining eligible cannabis purchases.